The rare disease biotech announced that it would discontinue efforts to develop Voxzogo for children with Noonan syndrome, a genetic growth disorder that can affect height, facial features and the heart.
In a deal that allows Sanofi to shed assets wrapped up in mature products, German drugmaker Cheplapharm will take over 20 medicines and three manufacturing sites from Sanofi. In exchange, Sanofi is picking up a 26.4% stake in the company.
Lindsey Vonn knows more than most about pain. Spending years training as an elite alpine ski racer puts enough pressure on your body, but Vonn’s injuries and her major crash earlier this year that nearly saw her lose her leg put her at a different level.
AbbVie has partnered with the PGA Tour and the 2026 Presidents Cup, teeing up the “Birdies for Brain Health” initiative to funnel cash to six patient advocacy organizations.
The FDA has approved the industry’s first radioligand equivalent in Curium’s lutetium Lu 177 dotatate injection, Bexlutry, after a court cleared the Boston company of all patent claims brought by Novartis.
Shionogi is stepping up promotion of COVID-19 drug Xocova, working with The Bloc on an omnichannel campaign designed to encourage people to contact their healthcare professional after being exposed to the virus.
Healthcare marketing and comms agency, Deerfield Group, is creating a new model for growth while making a series of appointments and promotions to help bolster its plans.
As the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously studied in the real world.
The injectable monoclonal antibody is the first to treat muscle atrophy in patients with SMA, according to the FDA.
GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.
Commercial plans can no longer be static. Acumetis' Swathi Rangan explains how teams can adapt strategy as markets evolve.
As Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major rebranding of its business, its logo and its name.
WuXi AppTec’s Ke Chen discusses trends reshaping API manufacturing – while diligence, understanding and controlling the process remains the cornerstone
Why are so many eligible patients still missing the therapies designed for them?
Why aren’t diagnostic-driven therapies reaching enough patients?
Real-world data has become table stakes. The next challenge is connecting it to genetic insight that can sharpen R&D decisions.
Dr. Rana McKay speaks to the ARANOTE trial of NUBEQA® (darolutamide) and what the data mean for patients, doctors, and care providers.
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an unprecedented complete response rate.
A preliminary 15% higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ADC Enhertu as a first-line treatment for patients with HER2-mutant non-small cell lung cancer.